BR112015029299A2 - subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares - Google Patents

subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares

Info

Publication number
BR112015029299A2
BR112015029299A2 BR112015029299A BR112015029299A BR112015029299A2 BR 112015029299 A2 BR112015029299 A2 BR 112015029299A2 BR 112015029299 A BR112015029299 A BR 112015029299A BR 112015029299 A BR112015029299 A BR 112015029299A BR 112015029299 A2 BR112015029299 A2 BR 112015029299A2
Authority
BR
Brazil
Prior art keywords
treatment
cells
monocyte subpopulation
disorders
eye diseases
Prior art date
Application number
BR112015029299A
Other languages
English (en)
Portuguese (pt)
Inventor
Yoles Ester
Benhar Bar-On Inbal
Eisenbach-Schwartz Michal
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR112015029299A2 publication Critical patent/BR112015029299A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015029299A 2013-05-22 2014-05-22 subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares BR112015029299A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361826159P 2013-05-22 2013-05-22
US201361915069P 2013-12-12 2013-12-12
PCT/IL2014/050463 WO2014188436A1 (en) 2013-05-22 2014-05-22 Human monocyte sub-population for treatment of eye diseases and disorders

Publications (1)

Publication Number Publication Date
BR112015029299A2 true BR112015029299A2 (pt) 2017-07-25

Family

ID=51933057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029299A BR112015029299A2 (pt) 2013-05-22 2014-05-22 subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares

Country Status (11)

Country Link
US (1) US10188679B2 (cg-RX-API-DMAC7.html)
EP (1) EP2999479B1 (cg-RX-API-DMAC7.html)
JP (1) JP6474082B2 (cg-RX-API-DMAC7.html)
KR (1) KR102257163B1 (cg-RX-API-DMAC7.html)
CN (1) CN105377273A (cg-RX-API-DMAC7.html)
AU (1) AU2014269935B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015029299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2913274C (cg-RX-API-DMAC7.html)
IL (1) IL242694B (cg-RX-API-DMAC7.html)
MX (1) MX2015016062A (cg-RX-API-DMAC7.html)
WO (1) WO2014188436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013088441A1 (en) * 2011-12-14 2013-06-20 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of central nervous system injury
US11162070B2 (en) 2015-09-08 2021-11-02 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
DE102017125335B4 (de) * 2017-10-27 2019-10-17 Epiontis Gmbh Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten
KR102228401B1 (ko) * 2018-07-05 2021-03-16 고려대학교 산학협력단 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델
MX2022007107A (es) * 2019-12-11 2022-11-14 Myeloid Therapeutics Inc Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
CN116440253A (zh) * 2023-02-27 2023-07-18 中山大学中山眼科中心 修复型免疫细胞亚群的诱导方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
AU2002353465B2 (en) 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
RU2418856C2 (ru) * 2005-02-24 2011-05-20 Дзе Скриппс Рисерч Инститьют Изолированные популяции миелоидоподобных клеток костного мозга и способы лечения с ними
AU2010216374A1 (en) * 2009-02-20 2011-08-18 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications
WO2013088441A1 (en) * 2011-12-14 2013-06-20 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of central nervous system injury

Also Published As

Publication number Publication date
JP2016522830A (ja) 2016-08-04
CA2913274A1 (en) 2014-11-27
EP2999479B1 (en) 2021-01-06
IL242694B (en) 2021-01-31
EP2999479A1 (en) 2016-03-30
JP6474082B2 (ja) 2019-02-27
EP2999479A4 (en) 2017-02-22
CA2913274C (en) 2021-10-12
AU2014269935B2 (en) 2019-01-24
KR20160016874A (ko) 2016-02-15
KR102257163B1 (ko) 2021-05-27
US20160166612A1 (en) 2016-06-16
MX2015016062A (es) 2016-08-03
CN105377273A (zh) 2016-03-02
US10188679B2 (en) 2019-01-29
WO2014188436A1 (en) 2014-11-27
AU2014269935A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
PH12019502254A1 (en) Methods and systems for modulating stimuli to the brain with biosensors
CY1123735T1 (el) Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης
EA201891224A1 (ru) Способы и системы для предоставления стимулов для головного мозга
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
UY33481A (es) Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular
BR112017014332A2 (pt) métodos de tratamento de doenças retinianas
ES2571991T3 (es) Procedimientos para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
MX2017009694A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
BR112018074454A2 (pt) composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
EA201000441A1 (ru) Водные офтальмологические препараты
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112014003704A2 (pt) moduladores ror gama
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
MX2015016062A (es) Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]